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Abstract
The management of Venous Thromboembolism in terms of treatments and prevention has been well researched for patients
who have been discovered as positive for Factor V Leiden genetic clotting disorder, in either the homozygous or the heterozygous genotype. In fact, the research and development of new agents called Direct oral anticoagulants aim to treat and prevent
clotting events while minimizing the risks of bleeding. Although several risk factors have been identified in relation to VTE, Factor
V Leiden mutation presents a seemingly higher risk due to its unpredictable incidences of clotting events, even in patients with
optimal health characteristics. Yet, we haven’t transitioned to routine testing of the common population for the Factor V Leiden
as a preventative measure, rather the focus has been on those at risk due to family history of VTE or if clinical decisions might
depend on it, such as the proper choice of contraception for female patients. Additionally, the increased risk of thrombophilia
during pregnancy raises concern for proper medical management that would benefit the mother, without harming the baby, at
any point of the pregnancy.
Introduction
For many people, the thought of having a blood clot is
terrifying and rightfully so because it is potentially fatal
and essentially invisible. A blood clot can appear in the leg,
in the lungs or even in the brain. Also called a thrombus, a
clot represents an accumulation of blood in a solid state,
essentially caused by coagulation processes. Although
coagulation is an important and vital function of homeostasis, the resultant clot formation may obstruct blood
vessels enough to limit perfusion of their field of supply.
Medicine has shown that many risk factors for developing
thrombi are acquired and depend on a patient’s physical or medical conditions such as obesity, hypertension,
atherosclerosis, or even pregnancy. However, different
genetic mutations appear to be linked to increased risk
of thrombosis, such as Factor V Leiden, named after the
city of Leiden in the Netherlands, where it was first identified while researching links between oral contraceptives
and increased cases of thrombosis (Vandenbroucke et
al., 1994). Factor V Leiden is the most common genetic
mutation causing increased risk of thrombophilia, or abnormal coagulation, therefore treatment options should
be carefully considered for patients with clotting history, as well as preventative measures for those who have
not presented with thrombi. In view of the association of
blood clots with family planning measures, this review will
focus on women with Factor V Leiden, considering female
individuals with or without a history of thrombophilia.
Background:
Pathophysiology of Factor V Leiden
The factor V Leiden thrombophilia, also called Activated
Protein C resistance, stems from a genetic mutation that
affects parts of the clotting cascade, a physiological process necessary for proper regulation of coagulation (Van
Cott et. al, 2016). More specifically, Activated Protein C
(APC), along with a cofactor Protein S, normally inactivates some coagulation factors, hence acting as an anticoagulant system. The mutation results in a decline in

that inactivation, which has the potential to increase the
coagulation activity. As for all genetic mutations, they can
be present as heterozygous with one abnormal copy of
the gene, or homozygous, for which both copies of the
gene are mutated, the latter increasing the risk for thrombophilia by 80-fold. Regarding the population distribution
of the Factor V Leiden mutation, it appears to be more
prevalent in Europe, followed by Africa, and less prevalent
in America (Rees, Cox, 1995).
Methods
To complete this review, multiple scientific scholar databases and peer-reviewed articles mainly found on the
Touro College online library were used. The Proquest,
Browzine, Google scholar, and Dynamed databases were
utilized with specific associations of key words in order
to optimize the research and the results necessary to
complete this study.
Discussion
When exploring the Factor V Leiden mutation and its
relation to increased risk of venous thrombosis, it is first
essential to make the distinction between individuals who
have had a previous clotting event such as a deep vein
thrombosis or a pulmonary embolism and those who
have not. In fact, treatment options, preventative measures
and family planning possibilities may be affected by a positive history of thrombophilia, regardless of the presence
of any physiological risk factors, not to be dismissed, but
to be utilized in conjunction with factor Factor V Leiden
mutation at the time of medical management (Anderson,
2003).Those risk factors should be touched upon for reference and comparison throughout this review.
Non-genetic Risk Factors of Venous Thrombosis
The risk factors for VTE (venous thromboembolism)
mainly consist of obesity, long periods of immobility,
surgery, smoking, age, pregnancy and use of oral contraceptive pills, according to the NYU VTEC center and the
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Figure 1: Most common risk factors of Venous Thromboembolism

Cornell center for blood disorders, both specializing in
venous thrombosis. Although common knowledge supports their statement, others might argue about the true
character of “risk factor” for some of the elements above
mentioned. For instance, obesity appears as a weak link
to increased VTE, based on multiple studies, therefore it
should be carefully analyzed when considering treatment
or even prophylaxis (Anderson, 2003). Similarly, although
age seems to count as a risk factor for many diseases or
medical complications, its direct connection to increased
VTE is questionable, especially due to the variety of ethnicities throughout the world and their life standards, as
described by an epidemiology review with respect to
China presenting an impressively low rate of DVT per
year (Cushman, 2007). Therefore, we should denote the
importance of evaluating an association of physiological
and potentially genetic risk factors when treating or preventing venous thrombosis.
Treatments and Preventions of Venous
Thromboembolism
It is essential to distinguish between patients who have
had a VTE event and those who haven’t, as it may affect
their treatment approach, even if they are positive for factor V Leiden. Additionally, this section will analyze whether treatments and preventions will be influenced by the
homozygous vs heterozygous factor V Leiden status.
When discussing treatment options, we refer to patients who have actually had a DVT or a pulmonary embolism and require treatment with anticoagulant. Although
the review focuses on patients with Factor V Leiden, it is
important to make the comparison with patients who do
not have any genetic mutation that would favor VTE, in
order to better understand the rationale for treatment
and prophylaxis.
22

Duration of Treatment
A minimum of 3-6 months of anticoagulation therapy is
recommended for all patients who suffered a VTE, regardless of physiological or genetic risk factors (Kearon, Akl,
2014). However, if a VTE is unprovoked, meaning without
obvious risk factor, it is highly recommended to pursue
anticoagulation for at least 12 months, or perhaps indefinitely to avoid recurrence, as highlighted by multiple
studies compiled in one of the articles on UPTODATE,
an online medical reference, that strongly emphasized the
reduction in rates of VTE recurrences in patients who
had been on anticoagulation long term (Lip, Russell, 2019).
Moreover, it is debatable whether a genetic mutation
causes unprovoked VTE or if it is provoked by the mutation. Even if provoked, opinions about the duration of
treatment vary widely, especially if the patient’s genotype
is heterozygous for factor V Leiden; in fact, many providers will not treat indefinitely for a VTE provoked by a
genetic factor, (Lip, Russell, 2019). More surprisingly, the
actual difference in VTE incidence between both Factor
V Leiden genotypes seems questionable. Indeed, when
analyzing the number of actual cases and the percentage
of recurrence after a first event, only a slim difference
between homozygous and heterozygous percentages in
VTE events (Perez Botero, Ormsby, 2016). Therefore, we
can argue that the Factor V Leiden genotype shouldn’t be
used alone to distinguish between lengths of treatment.
On a separate note, it is essential to take into consideration the bleeding risk associated with taking anticoagulant agents, commonly named “blood thinners”. As
a matter of fact, all anticoagulants increase the bleeding
risk to some extent and require vital risk versus benefit
assessment when initiating treatment for VTE and determining duration of treatment. Bleeding associated with
anticoagulation can range from a simple hematoma or
easy bruising, to life threatening gastrointestinal or intracranial hemorrhage (Garcia, Crowther, 2019). Evidently,
the longer a patient is on anticoagulation treatment, the
higher chances he/she has of developing internal bleeding
events, and those shouldn’t be taken lightly, therefore
must be investigated even with minimal symptoms, such
as coughing up a little blood. In fact, the Mayo clinic recommends precaution when prescribing blood thinners
especially to older patients (>75 years old) who present
higher chances of GI bleed (Harringa, 2019). On a similar
note, when treating a patient with factor V Leiden with
anticoagulation on a long-term basis, one ought to carefully monitor the bleeding effect of the prescribed agent.
Indeed, we can also include female patients with factor V
Leiden, for which continuous anticoagulation therapy will
result in heavier menstruations. Although, we previously
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argued that the factor V Leiden genotype alone doesn’t
determine the length of treatment, those patients will
need long term treatment since the factor V Leiden is a
genetic component, and by definition cannot just disappear, as opposed to obesity. Therefore, if it is a constant
risk factor, it will most likely represent a constant threat.
The next section will present various anticoagulants that
have been discovered and manufactured.
Different Anticoagulants on the Market

Table 1: Oral Anticoagulant comparative table

Based on the table above, multiple factors are to be considered when initiating a patient on oral therapy following
an acute VTE event, especially when the patient is positive
for factor V Leiden, and will most likely require long term
anticoagulation therapy The drug class can be taken into
account . In this case, both warfarin and the rest of the
agents called Direct Oral anticoagulants (DOACs) are
acceptable for treatment of VTE (Milling, Frontera, 2017).
Furthermore, the daily dosage varies among all AC agents,
from once a day with Warfarin or Xarelto, to twice a day
with Eliquis or Pradaxa. Therefore, it raises an obvious
question of medication compliance. Surely patients would
be more likely to comply with their medications if only
they needed to be taken once a day instead of twice a
day. In that respect, Warfarin or Xarelto seem to be optimal options. However, as indicated on the table above,
the daily dose of warfarin is dependent on a standardized

international blood test called INR. In fact, patients on
warfarin need to check their INR blood test quite often
as their dose of warfarin will be adjusted based upon the
results. Therefore, the frequent change of coumadin dosage undoubtedly will result in patients confused with dosage, that is without considering frequent venipunctures
to test the INR. In addition, warfarin is a vitamin K antagonist, which means all foods high in vitamin K will counteract the effect of coumadin; hence, those foods should
be avoided or eaten in small portions all throughout the
duration of the treatment with
warfarin; a factor to consider
greatly since a lot of greens or
even garlic can interact with warfarin (Mayo Clinic, 2018).
The next component of the
table includes the creatinine
clearance, representing a potential risk of certain DOAC agents
such as Xarelto, on the renal
function. Although it doesn’t directly concern a DVT or a PE,
certain patients who present
with blood clots events, may also
suffer from other medical conditions such as renal disease, which
in this case can render the choice
of AC more challenging.
The last component of the
table indicates the possibility
to reverse AC agents due to
overuse or excess bleeding for
example as a result of hypovolemic shock or major trauma.
Warfarin’s reversal agent is Vitamin K. Moreover, a reversal agent became approved by the FDA for both Eliquis
and Xarelto this year, by the name of Andexanet Alfa
(Cuker et. al., 2019).
Besides for the factors indicated on the table above, it
is essential to also mention the potential risks of bleeding
and consequent serious medical conditions such as GI
bleed and intracranial hemorrhage. According to multiple trials, it appears that DOACs have a lower risk of
intracranial hemorrhage or even GI hemorrhage than
warfarin and therefore should be used as a first choice,
if all contraindications have been carefully considered
(Garcia, Crowther 2019).
Additionally, considerations must be made for female
patients who are pregnant, because all the above-mentioned agents, whether Warfarin or DOACs are not indicated during any of the stages of pregnancy. Alternatives
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will need to be used as needed for treatment of a VTE
during pregnancy or even as a prophylactic agent; those
will be contemplated in the family planning section.
The duration of anticoagulation treatment varies with
the unprovoked versus provoked status of a VTE, in patients with either Factor V Leiden genotype, heterozygous
or homozygous. A blood thinner treatment is designed to
treat the current thrombosis, and even more importantly
to prevent recurrence. The nature of the AC agent will
depend on the availability of a reversible agent, the patient’s current renal status and the level of compliance a
provider attempts to achieve, apparently more in favor of
DOACs due to decreased risk of internal bleeding, compared to warfarin. Recent tendency has it to get tested
for genetic conditions such as Factor V Leiden, generally
due to family history of clotting.Therefore, if a patient has
a Factor V Leiden mutation, there may be some preventative measures to consider in certain cases, even if that
individual has never experienced a VTE.
Prevention of Venous Thromboembolism for
Patients with Factor V Leiden
There are several non-genetic risk factors to venous
thromboembolism (VTE), such as obesity, age, recent surgery or long immobilization states. If we also consider
the positive Factor V Leiden mutation genotypes, we can
understand that certain patients are at serious risk for
developing thrombi, whether from a physiological or genetic standpoint, or both. Moreover, patients who have
had a VTE can certainly develop another one, hence the
necessity for treatment, and preventative measures. Let’s
explore some risk factors and analyze the preventative
measures that would best benefit those at risk.
First of all, we can raise the question regarding testing
for genetic mutations such a factor V Leiden for patients
who have had a VTE or are family members of Factor V
Leiden. As a matter of fact, knowing that condition exists
can be part the prevention process. It seems that newborn or infant screening for Factor V Leiden or testing
of the population is not recommended, however the recommendations seem strong for female patients of child
bearing age with personal or family history of VTE, as well
as those under 50 years of age with a personal history
of Thromboembolism (Grody, et. al, 2001). While testing
family members of Factor V Leiden genotypes carriers is
important in certain cases, it appears it doesn’t necessarily
prevent the occurrence of VTE, unless those patients are
being educated on the mutation. It is especially important
to educate about VTE risks and implications in different
aspects of healthcare such as after a surgery, while on oral
contraceptive or even during pregnancy (Segal et. al, 2009).
24

Regarding the prophylactic interventions using medications, patients undergoing surgery or long-term immobilization following a surgery such as a knee or hip
replacement, will be offered anticoagulation prevention
via a low molecular weight heparin (LMWH). The most
common of those agents is called enoxaparin, with brand
name “Lovenox”, available as an injectable product, that
can be self-administered by the patient, but requires several calculations to determine proper dosage based on
weight and monitoring with a blood test called the “Anti
Xa activity” that calculates its efficacy (Busti, 2015). More
precisely, the LMWH acts as an inhibitor of a factor Xa,
one of several proteins involved in the coagulation cascade, which results in clotting formation, either in a normal ratio or abnormal, with consequences such as VTE. .
Another commonly used agent for prophylaxis, especially following a surgery, is warfarin, previously mentioned. In fact, it may seem undesirable for a lot of patients to go through daily injections. Although the use of
prophylaxis Warfarin has been associated with more than
50 % reduction of VTE post orthopedic surgery, LMWH
was concluded as a superior alternative for protection
against thromboembolism post-surgery (Paj, Douketis,
2019). Moreover, the use of low dose Aspirin has been
contemplated as well for prevention of VTE but is most
commonly used for cardiovascular prevention such as
protection from strokes or myocardial infarctions.
Although the goal of anticoagulant agents is for preventing VTE, the bleeding consequences are not to be
ignored. Therefore, hospital settings also offer non-pharmacological options such as an IPC device, intermittent
pneumatic compression device, that improves venous
circulations in upper and lower extremities to prevent
edema, as well as venous thromboembolism. However,
since data hasn’t shown the IPC device as a complete
alternative to medicated options, according to “uptodate”
latest research(Paj, Douketis, 2019), it is becoming common practice to start off with IPC devices for patients
with a high risk of bleeding, and then transition to a blood
thinner medication agent, as presented by the AHRQ, a
government agency in charge of research and quality in
healthcare systems (Maynard, 2016).
Testing for Factor V Leiden is not commonly done with
the general population but focuses on family members of
those with the genetic mutation. In regard to prophylaxis
agents for long term immobility, such as post-surgery,
different agents are available and will depend on the patient’s abilities to self-administer daily injections, as well as
the risk of bleeding, yet it is always important to measure
the levels of risk, especially for those patients with a
genetic component such as factor V Leiden mutation. The
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factor V Leiden genetic mutation was discovered in relation with increased risks of VTE for female patients on
oral contraception. Indeed, it appears that an important
amount of the research regarding Factor V Leiden thrombophilia is associated with female individuals and attend
to pregnancy or contraception related matters.
Female Patients with FactorV Leiden-Family Planning
Female patients of child-bearing age who are positive for
factor V Leiden need to be aware that their genotype can
affect their choices when dealing with contraception and
family planning.
Contraception
It is believed that oral contraceptives, especially estrogen
containing agents have the potential to increase the risk
of VTE; indeed, the estrogen will increase the plasma concentration of certain clotting factors and fibrinogen, all of
which are favorable to clotting formation (Busti, 2015).
Although several sources have pushed for testing
patients for Factor V Leiden prior to prescribing oral
contraceptives, it represents a large population of female
patients being tested and consequent precautions to be
taken for life with constant awareness of the genotype,
when there is no guarantee one of those women will
ever experience a thrombosis event. Rather, a review
suggests recording a comprehensive personal and familial
medical history or VTE when prescribing oral contraceptives (OCP) (Rosendaal, Koster, et. al, 1995), which seems
more appropriate and targeted.
It is important to understand that the association of
factor V Leiden and use of oral contraceptives cause great
thrombosis risk, and has been long studied and concluded
as such (Choe, Suh, 2019), therefore a female patient
should always mention it to her doctor before being
prescribed any oral contraceptives. Luckily, several contraceptive options have become available on the market
to satisfy all preferences and medical conditions, which
becomes handy for those with a history of VTE or known
Factor V Leiden. For example, the oral contraceptives
containing only progesterone have been categorized as
little to non-affecting coagulation. Therefore, these can
become an ideal option for those women at higher risk
of developing VTE, such as those with factor V Leiden
genotypes. Similarly, Intrauterine devices (IUD) containing only progestin, such as the Mirena, are an excellent
alternative to oral contraceptives for those who can’t
seem to comply to the daily regimen of birth control,
especially when indicated to be taken at the same time
every day. It is however essential to bring to light the fact
that fewer studies were conducted on progesterone-only

agents, therefore more data may be necessary to fully
draw the conclusion of its higher grade of safety in terms
of VTE prevention (Tchaikovski, Rosing, 2010). In addition,
The Journal of Community Hospital Internal Medicine
published an article this year warning about the progestin-only IUD, when a female patient in her early 30’s with
Factor V Leiden suffered a pulmonary embolism while on
that intrauterine device (Jean, 2019). Therefore, although
it appeared at first that only estrogen containing oral or
intrauterine agents were associated with increased risk
of VTE incidences, we find it questionable whether the
progestin only agents are truely safe alternative for those
patients at risk such as the Factor V Leiden genotypes,
or even those without the genotype but with a history
of clotting. Luckily for those individuals, there is now
a non-hormonal intrauterine device available such as
the Paragard IUD, releasing copper as a contraception
method, therefore seemingly the ideal option for those of
at VTE risk. In its mechanism, the copper acts as a toxic
environment for sperm, which significantly reduces the
chance for fertilization of the egg (Higginbotham, 2018).
Though it seems like the ideal option, it is interesting
to present the reported increase of menstrual bleeding
associated with the Copper Intrauterine device, as well as
cramping (Galan, 2016). Furthermore, the idea of having
an internal device can be disturbing for a lot of patients
and has shown serious medical consequences such as
ectopic pregnancies or infections, although only shown in
low percentages.
To sum it up, it appears that although ample options
are available on the market for contraception, the choices become limited for patients with Factor V Leiden or
patients with personal or even a family history of VTE.
Although intrauterine devices optimize compliance with
the regimen, they aren’t always the preferred options
for contraception due to their potential serious consequences. Ultimately, patients at risk of developing VTE
should resort to using the copper IUD, because it doesn’t
contain any hormones, despite its potential increase of
bleeding risk, which can be even more exacerbated for
those patients who already take daily anticoagulant.
Factor V Leiden plays an important role in a patient’s
choice for contraception, but also during pregnancy or
when planning to become pregnant.
Pregnancy
Pregnancy represents a risk factor on its own for Venous
Thromboembolism. During pregnancy, a patient will be
considered in a hypercoagulable state, or increased tendency to coagulate, due to higher levels of fibrinogen and
certain clotting factors, as well as a vascular damage or
25
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reshaping that the increase in weight and fluid can cause
(Gibson, Powrie, 2009). Following that thought process, a
risk factor should be avoided, or if cannot be, should be
carefully managed; in this case management of pregnancy
for patients at risk of VTE.
Patients with Factor V Leiden and/or those with a
history of VTE should carefully monitor their cycles as
to know when to get pregnant because of the high probability those individuals will need to modify the types of
AC they take. Multiple studies have examined the optimal
options for prophylaxis AC in patients who are at high
risk of developing VTE or those who have a history of
VTE. It appears that the current recommendations suggest the use of heparin injections throughout pregnancy
and up to 6 weeks after delivery, because heparin does
not cross the placenta and is not transmitted via breast
milk. Therefore, it is considered a relatively safe option
for both the mother and baby (Gibson, Powrie, 2009).
However, while Heparin is safe for pregnancy, it is important to distinguish between unfractionated heparin,
which has been linked to osteoporosis and thrombocytopenia when used long term, and low molecular weight
heparin (LMWH), with less incidence of the above mentioned (De Santis, et., al, 2006). An example of LMWH
is Lovenox, with the generic name enoxaparin, and has
demonstrated success as a prophylactic agent against
VTE in several instances world-wide, one of which was
reported regarding a young pregnant patient in Nigeria
with factor V Leiden homozygous who was treated with
LMWH during her pregnancy due to a DVT (Dogara, et,
al, 2018). Since pregnancy might occur while on an anticoagulant, it is essential for those individuals to be aware
of their cycles in order to start the appropriate AC agent
as soon as soon they become pregnant. The use of direct
oral anticoagulants (DOACs) are still contraindicated
during pregnancy. In fact, it is due to the lack of data proving them safe, the few results demonstrating a high rate
of miscarriage, as well as relatively significant amount of
fetal abnormalities for patients on DOACs, concluded to
be directly related to the DOACs, but poorly investigated
(Lameijer, et, al, 2018).
Female patients who are aware of a risk factor for
VTE, usually genetic such as factor V Leiden mutation, can
evidently be more prepared and educated on the precautions to take regarding anticoagulation management
during pregnancy. However, many patients in fact find out
about their Factor V Leiden mutation during pregnancy, as they experience a DVT or pulmonary embolism,
requiring emergency treatment with LMWH, or after
suffering multiple spontaneous miscarriages. Interestingly,
some studies have compared the rate of first trimester
26

miscarriages in patients with known factor V Leiden and
those with known regular genotype, and the incidence of
early pregnancy miscarriage doesn’t seem to have a close
relationship with Factor V Leiden. Rather it does when
comparing later term miscarriage, possibly caused by
clotting within the uterine vasculature (Jivraj, et., al, 2009).
Furthermore, while Factor V Leiden had been thought
more risky, it doesn’t appear to affect the management
of pregnant patients for VTE prevention, since several
studies have yet to discover significant differences in
clinical pictures between homozygous and heterozygous,
(Gat, et, al, 2014).
Other forms of prevention for VTE during pregnancy
include compression stockings however these have received a low grade of compliance among those women
due to discomfort. Moreover, it usually can improve
blood circulation in lower extremities but are limited to
lower extremities.
As with all patients, pregnant patients with factor V
Leiden should in addition keep a healthy lifestyle, combining a balanced diet and regular exercise, to keep proper
perfusion, for theirs and their babies’ sake.
Conclusion
The high incidences of VTE has stimulated much research
to find optimal forms of treatment and preventative
agents in the forms of Anticoagulants, whether oral or
injectable, for patients at higher risk of developing Venous
thromboembolism, such as those individuals with the
Factor V Leiden genetic mutation. Although the newer
DOACs have become more popular due to decreased
necessity for close monitoring, decreased bleeding risk,
and statistical efficiency in the prevention of thrombosis,
it appears they still cause issues for pregnant patients,
and require more extensive research to prove their safety. Fortunately, low molecular weight heparin injections
have been used for management of pregnant patients
since they don’t cross the placenta, and they have been
utilized often as a post-surgery prophylaxis on a shortterm basis. Regarding the management of patients who
wish to utilize contraception measures, careful attention
is to be applied due to the elevated clinical relationship
between the use of estrogen and episodes of VTE, but
unfortunately most of the contraceptive options do not
seem adequate for those high-risk female individuals,
therefore requiring further research and development.
Although Factor V Leiden appears to be the most popular genotype associated with VTE, multiple other genetic
mutations have close relationships with increased risk
of thrombosis. Since the pregnancy represents a high
risk factor on its own, perhaps the thought of prenatal
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testing with a thrombophilia panel doesn’t seem inadequate, although the question remains about a reasonable
response to the screenings in terms of prophylaxis, that
would be beneficial to patients’ physical health without
being detrimental to their mental health, once aware that
an important genetic mutation is present, especially at
sensitive times such as during pregnancy.
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